Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06764017 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CHiR Therapy for Elderly DLBCL Intolerant to Chemo

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
The objective of exploring the application of CHiR is to evaluate its therapeutic efficacy and safety in newly diagnosed elderly patients with diffuse large B-cell lymphoma (DLBCL) aged 70 and above, and to investigate the genetic subtypes that may benefit from CHiR. The primary endpoint is the complete remission rate (CRR) at the end of 8 cycles.
Trial Details
NCT Number NCT06764017
Lead Sponsor First Affiliated Hospital of Ningbo University
Conditions
(from sponsor)		 Diffuse Large B-Cell Lymphoma
Related terms Lymphoma, Large B-Cell, Diffuse
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov